R&D Empowerment, Win‑Win Cooperation | Leadingpharm’s Journey at the 92nd PHARMCHINA Concludes Successfully!

May 13–15, 2026 – The 92nd National Pharmaceutical Trade Fair (PHARMCHINA) was successfully held at the Shanghai National Exhibition and Convention Center. As an annual bellwether of the pharmaceutical and healthcare sector, this year’s event not only gathered global industry wisdom but also built an efficient industrial ecosystem. Leadingpharm made a strong appearance with its senior expert team, showcasing the company’s profound R&D capabilities across the entire pharmaceutical value chain, engaging in in‑depth exchanges with industry peers, and exploring new paths for pharmaceutical innovation and high‑quality development.

 

Throughout the fair, Leadingpharm’s booth maintained high foot traffic, serving as a key window for industry exchanges and business matchmaking. The company systematically presented its one‑stop pharmaceutical R&D solutions, covering innovative drug development, generic drug consistency evaluation, technology transfer, and project collaboration. Numerous pharmaceutical company representatives, R&D institution leaders, and industry experts stopped by to learn more about the company’s technology platforms, project management systems, and successful case studies, with lively on‑site negotiation atmosphere.
 

At the concurrent 92nd PHARMCHINA Lighthouse Sub‑forum – the 19th Pharmaceutical R&D Project Cooperation and Technology Transfer Conference, Dr. Zhang Xiang, Vice President of Leadingpharm, was invited to deliver a keynote speech. Dr. Zhang focused on “Addressing Core R&D Pain Points and Meeting Clients’ Key Demands,” leveraging Leadingpharm’s full‑industry‑chain service capabilities and extensive project experience to systematically analyze key industry issues such as risk control throughout the innovative drug R&D process, and pathways for generic drug differentiation under centralized procurement. The speech directly addressed real pain points, offering actionable and quantifiable solutions from R&D strategy optimization, cross‑stage quality control, and cost‑efficiency improvement, resonating strongly with the audience. After the speech, Dr. Zhang engaged in in‑depth discussions with attending experts and industry representatives on innovative drug R&D collaboration, generic technology transfer, and CXO resource synergy, laying a solid foundation for subsequent project commercialization.
 

This appearance at the 92nd PHARMCHINA fully demonstrated Leadingpharm’s technical strength, project experience, and full‑chain service capabilities in pharmaceutical R&D services, underscoring the company’s customer‑centric approach, focus on R&D pain points, and commitment to continuous industry empowerment. In the future, Leadingpharm will continue to deepen its pharmaceutical research and clinical services, optimize its innovative and generic drug R&D management models, enhance open industry cooperation, and contribute professional strength to technological innovation and achievement transformation in the pharmaceutical industry, thereby promoting high‑quality development of China’s healthcare sector.
 

About Us

Founded in 2005 and listed on the Shanghai Stock Exchange in 2015 (stock code: 600222), Leadingpharm is a premier supplier of full‑industry‑chain services including pharmaceutical CMC, clinical CRO, and MAH, serving global clients. It has been consistently ranked among the “Top 10 Pharmaceutical R&D Companies in China” by the All‑China Federation of Industry and Commerce. With a nearly 1,000‑member senior R&D team, a robust quality management system, and extensive project experience, the company provides customized solutions from product inception to commercial transformation.
 

-END-